Interleukin-22 and rheumatoid arthritis: Emerging role in pathogenesis and therapy

References

• Yuan, F. L., X. Li, W. G. Lu, et al. 2011. IL-33: a promising therapeutic target for rheumatoid arthritis? Expert Opin. Ther. Targets. 15: 529–534
   PubMed Web of Science ®Google Scholar
• Schulz, M., H. Dotzlaw, and G. Neeck. 2014. Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-alpha and its soluble receptors during the course of therapy with etanercept and infliximab. Biomed. Res. Int. 2014: Article ID 675108, 7 pages
   Google Scholar
• Bao, J., T. Yue, T. Li, et al. 2014. Good response to infliximab in rheumatoid arthritis following failure of interleukin-1 receptor antagonist. Int. J. Rheum. Dis. [Epub ahead of print]. doi: 10.1111/1756-185X.12387
   Google Scholar
• Curtis, J. R., F. Xie, L. Chen, et al. 2011. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann. Rheum. Dis. 70: 1401–1406
   PubMed Web of Science ®Google Scholar
• Raaschou, P., J. F. Simard, M. Holmqvist, et al. 2013. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 346: f1939
   PubMed Web of Science ®Google Scholar
• Dumoutier, L., J. Louahed, and J. C. Renauld. 2000. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J. Immunol. 164: 1814–1819
   PubMed Web of Science ®Google Scholar
• Dumoutier, L., E. Van Roost, G. Ameye, et al. 2000. IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes. Genes Immun. 1: 488–494
   PubMed Web of Science ®Google Scholar
• Renauld, J. C. 2003. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat. Rev. Immunol. 3: 667–676
   PubMedGoogle Scholar
• Kotenko, S. V., L. S. Izotova, O. V. Mirochnitchenko, et al. 2001. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J. Biol. Chem. 276: 2725–2732
   PubMed Web of Science ®Google Scholar
• Zenewicz, L. A., and R. A. Flavell. 2011. Recent advances in IL-22 biology. Int. Immunol. 23: 159–163
   PubMed Web of Science ®Google Scholar
• Zhao, L., Z. Jiang, Y. Jiang, et al. 2013. IL-22+ CD4+ T cells in patients with rheumatoid arthritis. Int. J. Rheum. Dis. 16: 518–526
   PubMedGoogle Scholar
• Zhang, L., Y. G. Li, Y. H. Li, et al. 2012. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One 7: e31000
   PubMed Web of Science ®Google Scholar
• Zhang, L., J. M. Li, X. G. Liu, et al. 2011. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J. Clin. Immunol. 31: 606–614
   PubMed Web of Science ®Google Scholar
• Leipe, J., M. A. Schramm, I. Prots, et al. 2014. Increased Th17 cell frequency and poor clinical outcome in rheumatoid arthritis are associated with a genetic variant in the IL4R gene, rs1805010. Arthritis Rheumatol. 66: 1165–1175
   PubMedGoogle Scholar
• Leipe, J., M. A. Schramm, M. Grunke, et al. 2011. Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis. Ann. Rheum. Dis. 70: 1453–1457
   PubMed Web of Science ®Google Scholar
• Kim, K. W., H. R. Kim, J. Y. Park, et al. 2012. Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheumatol. 64: 1015–1023
   PubMed Web of Science ®Google Scholar
• da Rocha, L. F. Jr., A. L. Duarte, A. T. Dantas, et al. 2012. Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. J. Rheumatol. 39: 1320–1325
   PubMed Web of Science ®Google Scholar
• Shen, H., J. C. Goodall, and J. S. Hill Gaston. 2009. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheumatol. 60: 1647–1656
   PubMed Web of Science ®Google Scholar
• Ikeuchi, H., T. Kuroiwa, N. Hiramatsu, et al. 2005. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheumatol. 52: 1037–1046
   PubMed Web of Science ®Google Scholar
• Marijnissen, R. J., M. I. Koenders, R. L. Smeets, et al. 2011. Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation. Arthritis Rheumatol. 63: 2939–2948
   PubMedGoogle Scholar
• Sarkar, S., X. Zhou, S. Justa, et al. 2013. Interleukin-22 reduces the severity of collagen-induced arthritis in association with increased levels of interleukin-10. Arthritis Rheumatol. 65: 960–971
   Google Scholar
• Carrion, M., Y. Juarranz, C. Martinez, et al. 2013. IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford) 52: 2177–2186
   PubMed Web of Science ®Google Scholar
• Mitra, A., S. K. Raychaudhuri, and S. P. Raychaudhuri. 2012. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. Cytokine 60: 38–42
   PubMed Web of Science ®Google Scholar
• Geboes, L., L. Dumoutier, H. Kelchtermans, et al. 2009. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheumatol. 60: 390–395
   PubMed Web of Science ®Google Scholar
• Justa, S., X. Zhou, and S. Sarkar. 2014. Endogenous IL-22 plays a dual role in arthritis: regulation of established arthritis via IFN-gamma responses. PLoS One 9: e93279
   Google Scholar
• Ren, J., Z. Feng, Z. Lv, et al. 2011. Natural killer-22 cells in the synovial fluid of patients with rheumatoid arthritis are an innate source of interleukin 22 and tumor necrosis factor-alpha. J. Rheumatol. 38: 2112–2118
   PubMedGoogle Scholar
• Abad, C., C. Martinez, M. G. Juarranz, et al. 2003. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124: 961–971
   PubMed Web of Science ®Google Scholar
• Carrion, M., Y. Juarranz, I. V. Seoane, et al. 2014. VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction. J. Mol. Neurosci. 52: 10–17
   PubMedGoogle Scholar
• Pereira, M. C., P. R. Cardoso, L. F. Da RochaJr., et al. 2014. Simvastatin inhibits cytokines in a dose response in patients with rheumatoid arthritis. Inflamm. Res. 63: 309–315
   PubMedGoogle Scholar
• da Rocha L. F., Jr. M. J. Rego, M. B. Cavalcanti, et al. 2013. Synthesis of a novel thiazolidinedione and evaluation of its modulatory effect on IFN-gamma, IL-6, IL-17A, and IL-22 production in PBMCs from rheumatoid arthritis patients. Biomed. Res. Int. 2013: Article ID 926060, 8 pages
   Google Scholar
• Colin, E. M., P. S. Asmawidjaja, J. P. van Hamburg, et al. 2010. 1,25-Dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheumatol. 62: 132–142
   PubMed Web of Science ®Google Scholar
• van de Veerdonk, F. L., B. Lauwerys, R. J. Marijnissen, et al. 2011. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheumatol. 63: 1507–1516
   PubMedGoogle Scholar